{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:48:49Z","timestamp":1792842529653,"version":"4.5.0"},"reference-count":172,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T00:00:00Z","timestamp":1568332800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T00:00:00Z","timestamp":1568332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["51777171"],"award-info":[{"award-number":["51777171"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81803032"],"award-info":[{"award-number":["81803032"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Fundamental Research Funds for the Central Universities","award":["3102017OQD111"],"award-info":[{"award-number":["3102017OQD111"]}]},{"name":"the Northwestern Polytechnical University Foundation for Fundamental Research","award":["3102018JGC012"],"award-info":[{"award-number":["3102018JGC012"]}]},{"DOI":"10.13039\/501100013093","name":"Science and Technology Planning Project of Shenzhen of China","doi-asserted-by":"crossref","award":["JCYJ20170412140904406"],"award-info":[{"award-number":["JCYJ20170412140904406"]}],"id":[{"id":"10.13039\/501100013093","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:p>Iron, an indispensable element for life, is involved in all kinds of important physiological activities. Iron promotes cell growth and proliferation, but it also causes oxidative stress damage. The body has a strict regulation mechanism of iron metabolism due to its potential toxicity. As a cancer of the bone marrow and blood cells, leukemia threatens human health seriously. Current studies suggest that dysregulation of iron metabolism and subsequent accumulation of excess iron are closely associated with the occurrence and progress of leukemia. Specifically, excess iron promotes the development of leukemia due to the pro-oxidative nature of iron and its damaging effects on DNA. On the other hand, leukemia cells acquire large amounts of iron to maintain rapid growth and proliferation. Therefore, targeting iron metabolism may provide new insights for approaches to the treatment of leukemia. This review summarizes physiologic iron metabolism, alternations of iron metabolism in leukemia and therapeutic opportunities of targeting the altered iron metabolism in leukemia, with a focus on acute leukemia.<\/jats:p>","DOI":"10.1186\/s13046-019-1397-3","type":"journal-article","created":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T07:03:46Z","timestamp":1568358226000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":144,"title":["Iron and leukemia: new insights for future treatments"],"prefix":"10.1186","volume":"38","author":[{"given":"Fang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanhuan","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangfu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5418-6240","authenticated-orcid":false,"given":"Peng","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,13]]},"reference":[{"key":"1397_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nchembio.1416","volume":"10","author":"SJ Dixon","year":"2014","unstructured":"Dixon SJ, Stockwell BR. The role of iron and reactive oxygen species in cell death. Nat Chem Biol. 2014;10:9\u201317.","journal-title":"Nat Chem Biol"},{"key":"1397_CR2","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.chemosphere.2017.05.039","volume":"182","author":"A Fischbacher","year":"2017","unstructured":"Fischbacher A, von Sonntag C, Schmidt TC. Hydroxyl radical yields in the Fenton process under various pH, ligand concentrations and hydrogen peroxide\/Fe (II) ratios. Chemosphere. 2017;182:738\u201344.","journal-title":"Chemosphere"},{"key":"1397_CR3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1146\/annurev-pathol-012513-104651","volume":"9","author":"JD Lambeth","year":"2014","unstructured":"Lambeth JD, Neish AS. Nox enzymes and new thinking on reactive oxygen: a double-edged sword revisited. Annu Rev Pathol. 2014;9:119\u201345.","journal-title":"Annu Rev Pathol"},{"key":"1397_CR4","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S1474-4422(14)70117-6","volume":"13","author":"RJ Ward","year":"2014","unstructured":"Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L. The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol. 2014;13:1045\u201360.","journal-title":"Lancet Neurol"},{"issue":"5","key":"1397_CR5","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.3390\/ijms19051545","volume":"19","author":"Liangfu Zhou","year":"2018","unstructured":"Zhou L, Zhao B, Zhang L, Wang S, Dong D, Lv H, Shang P. Alterations in Cellular Iron Metabolism Provide More Therapeutic Opportunities for Cancer. Int J Mol Sci. 2018;19:1545.","journal-title":"International Journal of Molecular Sciences"},{"key":"1397_CR6","doi-asserted-by":"crossref","unstructured":"Vinchi F, Porto G, Simmelbauer A, Altamura S, Passos ST, Garbowski M, Silva AMN, Spaich S, Seide SE, Sparla R, et al. Atherosclerosis is aggravated by iron overload and ameliorated by dietary and pharmacological iron restriction. Eur Heart J. 2019;00:1\u201316.","DOI":"10.1093\/eurheartj\/ehz112"},{"key":"1397_CR7","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/nrc3495","volume":"13","author":"SV Torti","year":"2013","unstructured":"Torti SV, Torti FM. Iron and cancer: more ore to be mined. Nat Rev Cancer. 2013;13:342\u201355.","journal-title":"Nat Rev Cancer"},{"key":"1397_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7\u201334.","journal-title":"CA Cancer J Clin"},{"key":"1397_CR9","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1080\/10428194.2016.1239257","volume":"58","author":"J Benadiba","year":"2017","unstructured":"Benadiba J, Rosilio C, Nebout M, Heimeroth V, Neffati Z, Popa A, et al. Iron chelation: an adjuvant therapy to target metabolism, growth and survival of murine PTEN-deficient T lymphoma and human T lymphoblastic leukemia\/lymphoma. Leuk Lymphoma. 2017;58:1433\u201345.","journal-title":"Leuk Lymphoma"},{"key":"1397_CR10","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.leukres.2014.06.016","volume":"38","author":"AE Kennedy","year":"2014","unstructured":"Kennedy AE, Kamdar KY, Lupo PJ, Okcu MF, Scheurer ME, Baum MK, et al. Examination of HFE associations with childhood leukemia risk and extension to other iron regulatory genes. Leuk Res. 2014;38:1055\u201360.","journal-title":"Leuk Res"},{"key":"1397_CR11","doi-asserted-by":"publisher","first-page":"610","DOI":"10.2174\/1871530318666180605094706","volume":"18","author":"AA Hagag","year":"2018","unstructured":"Hagag AA, Badraia IM, Abdelmageed MM, Hablas NM, Hazzaa SME, Nosair NA. Prognostic value of transferrin Receptor-1 (CD71) expression in acute lymphoblastic leukemia. Endocr Metab Immune Disord Drug Targets. 2018;18:610\u20137.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"1397_CR12","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","volume":"392","author":"NJ Short","year":"2018","unstructured":"Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392:593\u2013606.","journal-title":"Lancet"},{"key":"1397_CR13","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/j.mayocp.2016.09.010","volume":"91","author":"S Paul","year":"2016","unstructured":"Paul S, Kantarjian H, Jabbour EJ. Adult acute lymphoblastic leukemia. Mayo Clin Proc. 2016;91:1645\u201366.","journal-title":"Mayo Clin Proc"},{"key":"1397_CR14","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1084\/jem.20091488","volume":"207","author":"C Callens","year":"2010","unstructured":"Callens C, Coulon S, Naudin J, Radford-Weiss I, Boissel N, Raffoux E, et al. Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J Exp Med. 2010;207:731\u201350.","journal-title":"J Exp Med"},{"key":"1397_CR15","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1182\/blood-2011-12-399667","volume":"120","author":"M Roth","year":"2012","unstructured":"Roth M, Will B, Simkin G, Narayanagari S, Barreyro L, Bartholdy B, et al. Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. Blood. 2012;120:386\u201394.","journal-title":"Blood"},{"key":"1397_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.5045\/br.2015.50.1.33","volume":"50","author":"SR Jeon","year":"2015","unstructured":"Jeon SR, Lee JW, Jang PS, Chung NG, Cho B, Jeong DC. Anti-leukemic properties of deferasirox via apoptosis in murine leukemia cell lines. Blood Res. 2015;50:33\u20139.","journal-title":"Blood Res"},{"key":"1397_CR17","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1146\/annurev.nutr.23.011702.073139","volume":"23","author":"S Miret","year":"2003","unstructured":"Miret S, Simpson RJ, McKie AT. Physiology and molecular biology of dietary iron absorption. Annu Rev Nutr. 2003;23:283\u2013301.","journal-title":"Annu Rev Nutr"},{"key":"1397_CR18","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jtemb.2012.03.015","volume":"26","author":"BK Fuqua","year":"2012","unstructured":"Fuqua BK, Vulpe CD, Anderson GJ. Intestinal iron absorption. J Trace Elem Med Biol. 2012;26:115\u20139.","journal-title":"J Trace Elem Med Biol"},{"key":"1397_CR19","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.cmet.2005.01.003","volume":"1","author":"A Donovan","year":"2005","unstructured":"Donovan A, Lima CA, Pinkus JL, Pinkus GS, Zon LI, Robine S, et al. The iron exporter ferroportin\/Slc40a1 is essential for iron homeostasis. Cell Metab. 2005;1:191\u2013200.","journal-title":"Cell Metab"},{"key":"1397_CR20","doi-asserted-by":"publisher","first-page":"1559S","DOI":"10.3945\/ajcn.117.155804","volume":"106","author":"GJ Anderson","year":"2017","unstructured":"Anderson GJ, Frazer DM. Current understanding of iron homeostasis. Am J Clin Nutr. 2017;106:1559S\u201366S.","journal-title":"Am J Clin Nutr"},{"key":"1397_CR21","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.cell.2016.12.034","volume":"168","author":"MU Muckenthaler","year":"2017","unstructured":"Muckenthaler MU, Rivella S, Hentze MW, Galy B. A red carpet for iron metabolism. Cell. 2017;168:344\u201361.","journal-title":"Cell"},{"key":"1397_CR22","doi-asserted-by":"publisher","first-page":"G397","DOI":"10.1152\/ajpgi.00348.2013","volume":"307","author":"S Gulec","year":"2014","unstructured":"Gulec S, Anderson GJ, Collins JF. Mechanistic and regulatory aspects of intestinal iron absorption. Am J Physiol Gastrointest Liver Physiol. 2014;307:G397\u2013409.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"3","key":"1397_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BSR20150014","volume":"35","author":"Gautam Rishi","year":"2015","unstructured":"Rishi G, Wallace DF, Subramaniam VN. Hepcidin: regulation of the master iron regulator. Biosci Rep. 2015;35:e00192.","journal-title":"Bioscience Reports"},{"key":"1397_CR24","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/biof.1148","volume":"40","author":"DM Frazer","year":"2014","unstructured":"Frazer DM, Anderson GJ. The regulation of iron transport. Biofactors. 2014;40:206\u201314.","journal-title":"Biofactors"},{"key":"1397_CR25","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.bbagen.2011.07.008","volume":"1820","author":"JM El Hage Chahine","year":"2012","unstructured":"El Hage Chahine JM, Hemadi M, Ha-Duong NT. Uptake and release of metal ions by transferrin and interaction with receptor 1. Biochim Biophys Acta. 2012;1820:334\u201347.","journal-title":"Biochim Biophys Acta"},{"key":"1397_CR26","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/ng1658","volume":"37","author":"RS Ohgami","year":"2005","unstructured":"Ohgami RS, Campagna DR, Greer EL, Antiochos B, McDonald A, Chen J, et al. Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells. Nat Genet. 2005;37:1264\u20139.","journal-title":"Nat Genet"},{"key":"1397_CR27","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/S0891-5849(02)01006-7","volume":"33","author":"O Kakhlon","year":"2002","unstructured":"Kakhlon O, Cabantchik ZI. The labile iron pool: characterization, measurement, and participation in cellular processes (1). Free Radic Biol Med. 2002;33:1037\u201346.","journal-title":"Free Radic Biol Med"},{"key":"1397_CR28","doi-asserted-by":"publisher","first-page":"12764","DOI":"10.1074\/jbc.R117.791962","volume":"292","author":"CC Philpott","year":"2017","unstructured":"Philpott CC, Ryu MS, Frey A, Patel S. Cytosolic iron chaperones: proteins delivering iron cofactors in the cytosol of mammalian cells. J Biol Chem. 2017;292:12764\u201371.","journal-title":"J Biol Chem"},{"key":"1397_CR29","doi-asserted-by":"publisher","first-page":"10812","DOI":"10.1073\/pnas.96.19.10812","volume":"96","author":"ZL Harris","year":"1999","unstructured":"Harris ZL, Durley AP, Man TK, Gitlin JD. Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. Proc Natl Acad Sci U S A. 1999;96:10812\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1397_CR30","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3389\/fphar.2014.00176","volume":"5","author":"N Wilkinson","year":"2014","unstructured":"Wilkinson N, Pantopoulos K. The IRP\/IRE system in vivo: insights from mouse models. Front Pharmacol. 2014;5:176.","journal-title":"Front Pharmacol"},{"key":"1397_CR31","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1089\/ars.2014.5941","volume":"21","author":"A Ludin","year":"2014","unstructured":"Ludin A, Gur-Cohen S, Golan K, Kaufmann KB, Itkin T, Medaglia C, et al. Reactive oxygen species regulate hematopoietic stem cell self-renewal, migration and development, as well as their bone marrow microenvironment. Antioxid Redox Signal. 2014;21:1605\u201319.","journal-title":"Antioxid Redox Signal"},{"key":"1397_CR32","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2013-04-491944","volume":"122","author":"PS Hole","year":"2013","unstructured":"Hole PS, Zabkiewicz J, Munje C, Newton Z, Pearn L, White P, et al. Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling. Blood. 2013;122:3322\u201330.","journal-title":"Blood"},{"key":"1397_CR33","doi-asserted-by":"publisher","first-page":"8762","DOI":"10.1158\/0008-5472.CAN-06-4807","volume":"67","author":"FV Rassool","year":"2007","unstructured":"Rassool FV, Gaymes TJ, Omidvar N, Brady N, Beurlet S, Pla M, et al. Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia? Cancer Res. 2007;67:8762\u201371.","journal-title":"Cancer Res"},{"key":"1397_CR34","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1158\/1055-9965.EPI-13-0733","volume":"23","author":"A Fonseca-Nunes","year":"2014","unstructured":"Fonseca-Nunes A, Jakszyn P, Agudo A. Iron and cancer risk--a systematic review and meta-analysis of the epidemiological evidence. Cancer Epidemiol Biomark Prev. 2014;23:12\u201331.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1397_CR35","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/nyas.13008","volume":"1368","author":"DH Manz","year":"2016","unstructured":"Manz DH, Blanchette NL, Paul BT, Torti FM, Torti SV. Iron and cancer: recent insights. Ann N Y Acad Sci. 2016;1368:149\u201361.","journal-title":"Ann N Y Acad Sci"},{"key":"1397_CR36","doi-asserted-by":"publisher","first-page":"5832","DOI":"10.1182\/blood-2011-11-391722","volume":"119","author":"J Aurelius","year":"2012","unstructured":"Aurelius J, Thoren FB, Akhiani AA, Brune M, Palmqvist L, Hansson M, et al. Monocytic AML cells inactivate antileukemic lymphocytes: role of NADPH oxidase\/gp91(phox) expression and the PARP-1\/PAR pathway of apoptosis. Blood. 2012;119:5832\u20137.","journal-title":"Blood"},{"key":"1397_CR37","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s00277-017-2985-y","volume":"96","author":"J Chen","year":"2017","unstructured":"Chen J, Lu WY, Zhao MF, Cao XL, Jiang YY, Jin X, et al. Reactive oxygen species mediated T lymphocyte abnormalities in an iron-overloaded mouse model and iron-overloaded patients with myelodysplastic syndromes. Ann Hematol. 2017;96:1085\u201395.","journal-title":"Ann Hematol"},{"key":"1397_CR38","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.leukres.2015.05.001","volume":"39","author":"D Lebon","year":"2015","unstructured":"Lebon D, Vergez F, Bertoli S, Harrivel V, De Botton S, Micol JB, et al. Hyperferritinemia at diagnosis predicts relapse and overall survival in younger AML patients with intermediate-risk cytogenetics. Leuk Res. 2015;39:818\u201321.","journal-title":"Leuk Res"},{"key":"1397_CR39","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1182\/blood.V73.1.74.74","volume":"73","author":"HE Broxmeyer","year":"1989","unstructured":"Broxmeyer HE, Williams DE, Geissler K, Hangoc G, Cooper S, Bicknell DC, et al. Suppressive effects in vivo of purified recombinant human H-subunit (acidic) ferritin on murine myelopoiesis. Blood. 1989;73:74\u20139.","journal-title":"Blood"},{"key":"1397_CR40","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/ejh.13183","volume":"102","author":"S Bertoli","year":"2019","unstructured":"Bertoli S, Paubelle E, Berard E, Saland E, Thomas X, Tavitian S, et al. Ferritin heavy\/light chain (FTH1\/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemia. Eur J Haematol. 2019;102:131\u201342.","journal-title":"Eur J Haematol"},{"key":"1397_CR41","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.bbmt.2014.04.024","volume":"20","author":"P Armand","year":"2014","unstructured":"Armand P, Kim HT, Virtanen JM, Parkkola RK, Itala-Remes MA, Majhail NS, et al. Iron overload in allogeneic hematopoietic cell transplantation outcome: a meta-analysis. Biol Blood Marrow Transplant. 2014;20:1248\u201351.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1397_CR42","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1182\/blood-2006-10-054924","volume":"109","author":"P Armand","year":"2007","unstructured":"Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood. 2007;109:4586\u20138.","journal-title":"Blood"},{"key":"1397_CR43","doi-asserted-by":"crossref","first-page":"491058","DOI":"10.1155\/2011\/491058","volume":"2011","author":"AK Eisfeld","year":"2011","unstructured":"Eisfeld AK, Westerman M, Krahl R, Leiblein S, Liebert UG, Hehme M, et al. Highly elevated serum Hepcidin in patients with acute myeloid leukemia prior to and after allogeneic hematopoietic cell transplantation: does this protect from excessive parenchymal iron loading? Adv Hematol. 2011;2011:491058.","journal-title":"Adv Hematol"},{"key":"1397_CR44","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/j.1365-2362.2011.02608.x","volume":"42","author":"PP Cheng","year":"2012","unstructured":"Cheng PP, Sun ZZ, Jiang F, Tang YT, Jiao XY. Hepcidin expression in patients with acute leukaemia. Eur J Clin Investig. 2012;42:517\u201325.","journal-title":"Eur J Clin Investig"},{"key":"1397_CR45","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/sj.onc.1210711","volume":"27","author":"MJ Brookes","year":"2008","unstructured":"Brookes MJ, Boult J, Roberts K, Cooper BT, Hotchin NA, Matthews G, et al. A role for iron in Wnt signalling. Oncogene. 2008;27:966\u201375.","journal-title":"Oncogene"},{"key":"1397_CR46","doi-asserted-by":"publisher","first-page":"17646","DOI":"10.1074\/jbc.M210905200","volume":"278","author":"S Xiong","year":"2003","unstructured":"Xiong S, She H, Takeuchi H, Han B, Engelhardt JF, Barton CH, et al. Signaling role of intracellular iron in NF-kappaB activation. J Biol Chem. 2003;278:17646\u201354.","journal-title":"J Biol Chem"},{"issue":"9","key":"1397_CR47","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3390\/cancers8090078","volume":"8","author":"Frank Staal","year":"2016","unstructured":"Staal FJT, Famili F, Garcia Perez L, Pike-Overzet K. Aberrant Wnt Signaling in Leukemia. Cancers (Basel). 2016;8:78.","journal-title":"Cancers"},{"key":"1397_CR48","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1172\/JCI68101","volume":"124","author":"Y Kagoya","year":"2014","unstructured":"Kagoya Y, Yoshimi A, Kataoka K, Nakagawa M, Kumano K, Arai S, et al. Positive feedback between NF-kappaB and TNF-alpha promotes leukemia-initiating cell capacity. J Clin Invest. 2014;124:528\u201342.","journal-title":"J Clin Invest"},{"key":"1397_CR49","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.critrevonc.2015.11.017","volume":"99","author":"JB Porter","year":"2016","unstructured":"Porter JB, de Witte T, Cappellini MD, Gattermann N. New insights into transfusion-related iron toxicity: implications for the oncologist. Crit Rev Oncol Hematol. 2016;99:261\u201371.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1397_CR50","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/ejh.12159","volume":"91","author":"W Lu","year":"2013","unstructured":"Lu W, Zhao M, Rajbhandary S, Xie F, Chai X, Mu J, et al. Free iron catalyzes oxidative damage to hematopoietic cells\/mesenchymal stem cells in vitro and suppresses hematopoiesis in iron overload patients. Eur J Haematol. 2013;91:249\u201361.","journal-title":"Eur J Haematol"},{"key":"1397_CR51","doi-asserted-by":"publisher","first-page":"10181","DOI":"10.1038\/srep10181","volume":"5","author":"X Chai","year":"2015","unstructured":"Chai X, Li D, Cao X, Zhang Y, Mu J, Lu W, et al. ROS-mediated iron overload injures the hematopoiesis of bone marrow by damaging hematopoietic stem\/progenitor cells in mice. Sci Rep. 2015;5:10181.","journal-title":"Sci Rep"},{"key":"1397_CR52","doi-asserted-by":"publisher","first-page":"892","DOI":"10.3109\/10428194.2013.819100","volume":"55","author":"Q Liu","year":"2014","unstructured":"Liu Q, Wang M, Hu Y, Xing H, Chen X, Zhang Y, et al. Significance of CD71 expression by flow cytometry in diagnosis of acute leukemia. Leuk Lymphoma. 2014;55:892\u20138.","journal-title":"Leuk Lymphoma"},{"key":"1397_CR53","doi-asserted-by":"publisher","first-page":"310","DOI":"10.4103\/0377-4929.188145","volume":"59","author":"A Pande","year":"2016","unstructured":"Pande A, Dorwal P, Jain D, Tyagi N, Mehra S, Sachdev R, et al. Expression of CD71 by flow cytometry in acute leukemias: more often seen in acute myeloid leukemia. Indian J Pathol Microbiol. 2016;59:310\u20133.","journal-title":"Indian J Pathol Microbiol"},{"key":"1397_CR54","doi-asserted-by":"publisher","first-page":"304","DOI":"10.5603\/FHC.2012.0040","volume":"50","author":"A Ploszynska","year":"2012","unstructured":"Ploszynska A, Ruckemann-Dziurdzinska K, Jozwik A, Mikosik A, Lisowska K, Balcerska A, et al. Cytometric evaluation of transferrin receptor 1 (CD71) in childhood acute lymphoblastic leukemia. Folia Histochem Cytobiol. 2012;50:304\u201311.","journal-title":"Folia Histochem Cytobiol"},{"key":"1397_CR55","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1182\/blood.V98.9.2714","volume":"98","author":"H Kawabata","year":"2001","unstructured":"Kawabata H, Nakamaki T, Ikonomi P, Smith RD, Germain RS, Koeffler HP. Expression of transferrin receptor 2 in normal and neoplastic hematopoietic cells. Blood. 2001;98:2714\u20139.","journal-title":"Blood"},{"key":"1397_CR56","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/j.1365-2141.2004.04866.x","volume":"125","author":"T Nakamaki","year":"2004","unstructured":"Nakamaki T, Kawabata H, Saito B, Matsunawa M, Suzuki J, Adachi D, et al. Elevated levels of transferrin receptor 2 mRNA, not transferrin receptor 1 mRNA, are associated with increased survival in acute myeloid leukaemia. Br J Haematol. 2004;125:42\u20139.","journal-title":"Br J Haematol"},{"key":"1397_CR57","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1080\/10428190600821898","volume":"47","author":"A Viola","year":"2006","unstructured":"Viola A, Pagano L, Laudati D, D'Elia R, D'Amico MR, Ammirabile M, et al. HFE gene mutations in patients with acute leukemia. Leuk Lymphoma. 2006;47:2331\u20134.","journal-title":"Leuk Lymphoma"},{"key":"1397_CR58","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1080\/10428190290011930","volume":"43","author":"MT Dorak","year":"2002","unstructured":"Dorak MT, Burnett AK, Worwood M. Hemochromatosis gene in leukemia and lymphoma. Leuk Lymphoma. 2002;43:467\u201377.","journal-title":"Leuk Lymphoma"},{"key":"1397_CR59","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1182\/blood-2006-02-003681","volume":"108","author":"RS Ohgami","year":"2006","unstructured":"Ohgami RS, Campagna DR, McDonald A, Fleming MD. The Steap proteins are metalloreductases. Blood. 2006;108:1388\u201394.","journal-title":"Blood"},{"key":"1397_CR60","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.bbrc.2012.10.123","volume":"429","author":"J Moreaux","year":"2012","unstructured":"Moreaux J, Kassambara A, Hose D, Klein B. STEAP1 is overexpressed in cancers: a promising therapeutic target. Biochem Biophys Res Commun. 2012;429:148\u201355.","journal-title":"Biochem Biophys Res Commun"},{"key":"1397_CR61","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.phrs.2017.03.018","volume":"120","author":"M Jung","year":"2017","unstructured":"Jung M, Mertens C, Bauer R, Rehwald C, Brune B. Lipocalin-2 and iron trafficking in the tumor microenvironment. Pharmacol Res. 2017;120:146\u201356.","journal-title":"Pharmacol Res"},{"issue":"9","key":"1397_CR62","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3390\/cancers10090336","volume":"10","author":"Brigitte Bauvois","year":"2018","unstructured":"Bauvois B, Susin SA. Revisiting neutrophil gelatinase-associated Lipocalin (NGAL) in cancer: saint or sinner? Cancers (Basel). 2018;10:336.","journal-title":"Cancers"},{"key":"1397_CR63","doi-asserted-by":"publisher","first-page":"796","DOI":"10.3390\/cancers6020796","volume":"6","author":"S Bouchet","year":"2014","unstructured":"Bouchet S, Bauvois B. Neutrophil gelatinase-associated Lipocalin (NGAL), pro-matrix Metalloproteinase-9 (pro-MMP-9) and their complex pro-MMP-9\/NGAL in Leukaemias. Cancers (Basel). 2014;6:796\u2013812.","journal-title":"Cancers (Basel)"},{"key":"1397_CR64","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.18632\/oncotarget.1738","volume":"5","author":"S Candido","year":"2014","unstructured":"Candido S, Maestro R, Polesel J, Catania A, Maira F, Signorelli SS, et al. Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer. Oncotarget. 2014;5:1576\u201394.","journal-title":"Oncotarget"},{"key":"1397_CR65","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/j.1365-2141.2004.04877.x","volume":"125","author":"AS Kamiguti","year":"2004","unstructured":"Kamiguti AS, Lee ES, Till KJ, Harris RJ, Glenn MA, Lin K, et al. The role of matrix metalloproteinase 9 in the pathogenesis of chronic lymphocytic leukaemia. Br J Haematol. 2004;125:128\u201340.","journal-title":"Br J Haematol"},{"key":"1397_CR66","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1080\/10428190801942360","volume":"49","author":"C Villalva","year":"2008","unstructured":"Villalva C, Sorel N, Bonnet ML, Guilhot J, Mayeur-Rousse C, Guilhot F, et al. Neutrophil gelatinase-associated lipocalin expression in chronic myeloid leukemia. Leuk Lymphoma. 2008;49:984\u20138.","journal-title":"Leuk Lymphoma"},{"key":"1397_CR67","doi-asserted-by":"publisher","first-page":"6110","DOI":"10.1038\/onc.2008.209","volume":"27","author":"X Leng","year":"2008","unstructured":"Leng X, Lin H, Ding T, Wang Y, Wu Y, Klumpp S, et al. Lipocalin 2 is required for BCR-ABL-induced tumorigenesis. Oncogene. 2008;27:6110\u20139.","journal-title":"Oncogene"},{"key":"1397_CR68","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1200\/JCO.2009.23.4732","volume":"28","author":"T Haferlach","year":"2010","unstructured":"Haferlach T, Kohlmann A, Wieczorek L, Basso G, Kronnie GT, Bene MC, et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the international microarray innovations in leukemia study group. J Clin Oncol. 2010;28:2529\u201337.","journal-title":"J Clin Oncol"},{"key":"1397_CR69","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.3109\/10428194.2012.749402","volume":"54","author":"WC Yang","year":"2013","unstructured":"Yang WC, Lin PM, Yang MY, Liu YC, Chang CS, Chou WC, et al. Higher lipocalin 2 expression may represent an independent favorable prognostic factor in cytogenetically normal acute myeloid leukemia. Leuk Lymphoma. 2013;54:1614\u201325.","journal-title":"Leuk Lymphoma"},{"key":"1397_CR70","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1126\/science.283.5402.676","volume":"283","author":"KJ Wu","year":"1999","unstructured":"Wu KJ, Polack A, Dalla-Favera R. Coordinated regulation of iron-controlling genes, H-ferritin and IRP2, by c-MYC. Science. 1999;283:676\u20139.","journal-title":"Science"},{"key":"1397_CR71","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1182\/blood-2006-01-0172","volume":"108","author":"DP Smith","year":"2006","unstructured":"Smith DP, Bath ML, Metcalf D, Harris AW, Cory S. MYC levels govern hematopoietic tumor type and latency in transgenic mice. Blood. 2006;108:653\u201361.","journal-title":"Blood"},{"key":"1397_CR72","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1126\/science.1080280","volume":"299","author":"DM Langenau","year":"2003","unstructured":"Langenau DM, Traver D, Ferrando AA, Kutok JL, Aster JC, Kanki JP, et al. Myc-induced T cell leukemia in transgenic zebrafish. Science. 2003;299:887\u201390.","journal-title":"Science"},{"key":"1397_CR73","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1182\/blood-2013-08-522698","volume":"123","author":"JE Roderick","year":"2014","unstructured":"Roderick JE, Tesell J, Shultz LD, Brehm MA, Greiner DL, Harris MH, et al. C-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood. 2014;123:1040\u201350.","journal-title":"Blood"},{"key":"1397_CR74","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.cell.2004.10.017","volume":"119","author":"CG Pham","year":"2004","unstructured":"Pham CG, Bubici C, Zazzeroni F, Papa S, Jones J, Alvarez K, et al. Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell. 2004;119:529\u201342.","journal-title":"Cell"},{"key":"1397_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.leukres.2019.02.011","volume":"80","author":"M Gasparetto","year":"2019","unstructured":"Gasparetto M, Pei S, Minhajuddin M, Stevens B, Smith CA, Seligman P. Low ferroportin expression in AML is correlated with good risk cytogenetics, improved outcomes and increased sensitivity to chemotherapy. Leuk Res. 2019;80:1\u201310.","journal-title":"Leuk Res"},{"issue":"6","key":"1397_CR76","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41565-019-0406-1","volume":"14","author":"Vicenta Trujillo-Alonso","year":"2019","unstructured":"Trujillo-Alonso V, Pratt EC, Zong H, Lara-Martinez A, Kaittanis C, Rabie MO, Longo V, Becker MW, Roboz GJ, Grimm J, et al. FDA-approved ferumoxytol displays anti-leukaemia efficacy against cells with low ferroportin levels. Nat Nanotechnol. 2019;14:616\u201322.","journal-title":"Nature Nanotechnology"},{"key":"1397_CR77","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1158\/0008-5472.CAN-14-2465","volume":"75","author":"L Tesfay","year":"2015","unstructured":"Tesfay L, Clausen KA, Kim JW, Hegde P, Wang X, Miller LD, et al. Hepcidin regulation in prostate and its disruption in prostate cancer. Cancer Res. 2015;75:2254\u201363.","journal-title":"Cancer Res"},{"key":"1397_CR78","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1182\/blood-2006-02-002394","volume":"107","author":"EJ Neufeld","year":"2006","unstructured":"Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood. 2006;107:3436\u201341.","journal-title":"Blood"},{"key":"1397_CR79","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/ejh.12507","volume":"95","author":"MS Elalfy","year":"2015","unstructured":"Elalfy MS, Adly AM, Wali Y, Tony S, Samir A, Elhenawy YI. Efficacy and safety of a novel combination of two oral chelators deferasirox\/deferiprone over deferoxamine\/deferiprone in severely iron overloaded young beta thalassemia major patients. Eur J Haematol. 2015;95:411\u201320.","journal-title":"Eur J Haematol"},{"key":"1397_CR80","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1021\/tx100125t","volume":"23","author":"P Bendova","year":"2010","unstructured":"Bendova P, Mackova E, Haskova P, Vavrova A, Jirkovsky E, Sterba M, et al. Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury. Chem Res Toxicol. 2010;23:1105\u201314.","journal-title":"Chem Res Toxicol"},{"key":"1397_CR81","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.3324\/haematol.2009.016824","volume":"95","author":"E Messa","year":"2010","unstructured":"Messa E, Carturan S, Maffe C, Pautasso M, Bracco E, Roetto A, et al. Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica. 2010;95:1308\u201316.","journal-title":"Haematologica"},{"key":"1397_CR82","doi-asserted-by":"publisher","first-page":"15413","DOI":"10.1074\/jbc.M111.225946","volume":"286","author":"Y Yu","year":"2011","unstructured":"Yu Y, Richardson DR. Cellular iron depletion stimulates the JNK and p38 MAPK signaling transduction pathways, dissociation of ASK1-thioredoxin, and activation of ASK1. J Biol Chem. 2011;286:15413\u201327.","journal-title":"J Biol Chem"},{"key":"1397_CR83","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/0024-3205(92)90572-7","volume":"50","author":"T Furukawa","year":"1992","unstructured":"Furukawa T, Naitoh Y, Kohno H, Tokunaga R, Taketani S. Iron deprivation decreases ribonucleotide reductase activity and DNA synthesis. Life Sci. 1992;50:2059\u201365.","journal-title":"Life Sci"},{"key":"1397_CR84","doi-asserted-by":"publisher","first-page":"20291","DOI":"10.1074\/jbc.271.34.20291","volume":"271","author":"CE Cooper","year":"1996","unstructured":"Cooper CE, Lynagh GR, Hoyes KP, Hider RC, Cammack R, Porter JB. The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J Biol Chem. 1996;271:20291\u20139.","journal-title":"J Biol Chem"},{"key":"1397_CR85","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/bjh.13381","volume":"170","author":"T Tataranni","year":"2015","unstructured":"Tataranni T, Agriesti F, Mazzoccoli C, Ruggieri V, Scrima R, Laurenzana I, et al. The iron chelator deferasirox affects redox signalling in haematopoietic stem\/progenitor cells. Br J Haematol. 2015;170:236\u201346.","journal-title":"Br J Haematol"},{"key":"1397_CR86","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nature08313","volume":"461","author":"E Owusu-Ansah","year":"2009","unstructured":"Owusu-Ansah E, Banerjee U. Reactive oxygen species prime drosophila haematopoietic progenitors for differentiation. Nature. 2009;461:537\u201341.","journal-title":"Nature"},{"key":"1397_CR87","doi-asserted-by":"publisher","first-page":"7628","DOI":"10.1158\/0008-5472.CAN-11-2745","volume":"71","author":"S Song","year":"2011","unstructured":"Song S, Christova T, Perusini S, Alizadeh S, Bao RY, Miller BW, et al. Wnt inhibitor screen reveals iron dependence of beta-catenin signaling in cancers. Cancer Res. 2011;71:7628\u201339.","journal-title":"Cancer Res"},{"key":"1397_CR88","doi-asserted-by":"crossref","first-page":"36517","DOI":"10.18632\/oncotarget.16583","volume":"8","author":"N Li","year":"2017","unstructured":"Li N, Chen Q, Gu J, Li S, Zhao G, Wang W, et al. Synergistic inhibitory effects of deferasirox in combination with decitabine on leukemia cell lines SKM-1, THP-1, and K-562. Oncotarget. 2017;8:36517\u201330.","journal-title":"Oncotarget"},{"key":"1397_CR89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2017.1280604","volume":"58","author":"YC Chang","year":"2017","unstructured":"Chang YC, Lo WJ, Huang YT, Lin CL, Feng CC, Lin HT, et al. Deferasirox has strong anti-leukemia activity but may antagonize theanti-leukemia effect of doxorubicin. Leuk Lymphoma. 2017;58:1\u201312.","journal-title":"Leuk Lymphoma"},{"key":"1397_CR90","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cbi.2012.03.010","volume":"197","author":"E Mackova","year":"2012","unstructured":"Mackova E, Hruskova K, Bendova P, Vavrova A, Jansova H, Haskova P, et al. Methyl and ethyl ketone analogs of salicylaldehyde isonicotinoyl hydrazone: novel iron chelators with selective antiproliferative action. Chem Biol Interact. 2012;197:69\u201379.","journal-title":"Chem Biol Interact"},{"key":"1397_CR91","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1182\/blood-2004-03-0868","volume":"104","author":"J Yuan","year":"2004","unstructured":"Yuan J, Lovejoy DB, Richardson DR. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood. 2004;104:1450\u20138.","journal-title":"Blood"},{"key":"1397_CR92","first-page":"1259","volume":"1","author":"D Brooks","year":"1995","unstructured":"Brooks D, Taylor C, Dos Santos B, Linden H, Houghton A, Hecht TT, et al. Phase Ia trial of murine immunoglobulin a antitransferrin receptor antibody 42\/6. Clin Cancer Res. 1995;1:1259\u201365.","journal-title":"Clin Cancer Res"},{"key":"1397_CR93","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1182\/blood.V69.3.757.757","volume":"69","author":"Z Estrov","year":"1987","unstructured":"Estrov Z, Tawa A, Wang XH, Dube ID, Sulh H, Cohen A, et al. In vitro and in vivo effects of deferoxamine in neonatal acute leukemia. Blood. 1987;69:757\u201361.","journal-title":"Blood"},{"key":"1397_CR94","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/0006-291X(83)91040-9","volume":"110","author":"L Thelander","year":"1983","unstructured":"Thelander L, Graslund A, Thelander M. Continual presence of oxygen and iron required for mammalian ribonucleotide reduction: possible regulation mechanism. Biochem Biophys Res Commun. 1983;110:859\u201365.","journal-title":"Biochem Biophys Res Commun"},{"key":"1397_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejphar.2008.03.059","volume":"589","author":"M Gharagozloo","year":"2008","unstructured":"Gharagozloo M, Khoshdel Z, Amirghofran Z. The effect of an iron (III) chelator, silybin, on the proliferation and cell cycle of Jurkat cells: a comparison with desferrioxamine. Eur J Pharmacol. 2008;589:1\u20137.","journal-title":"Eur J Pharmacol"},{"key":"1397_CR96","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1182\/blood-2007-03-076737","volume":"110","author":"D Fu","year":"2007","unstructured":"Fu D, Richardson DR. Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1\/WAF1 by iron depletion. Blood. 2007;110:752\u201361.","journal-title":"Blood"},{"key":"1397_CR97","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1084\/jem.20100523","volume":"207","author":"O Abdel-Wahab","year":"2010","unstructured":"Abdel-Wahab O, Levine RL. Metabolism and the leukemic stem cell. J Exp Med. 2010;207:677\u201380.","journal-title":"J Exp Med"},{"key":"1397_CR98","doi-asserted-by":"publisher","first-page":"7365","DOI":"10.1158\/1078-0432.CCR-04-0865","volume":"10","author":"TB Chaston","year":"2004","unstructured":"Chaston TB, Watts RN, Yuan J, Richardson DR. Potent antitumor activity of novel iron chelators derived from di-2-pyridylketone isonicotinoyl hydrazone involves Fenton-derived free radical generation. Clin Cancer Res. 2004;10:7365\u201374.","journal-title":"Clin Cancer Res"},{"key":"1397_CR99","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1182\/blood-2004-07-2686","volume":"105","author":"G Regis","year":"2005","unstructured":"Regis G, Bosticardo M, Conti L, De Angelis S, Boselli D, Tomaino B, et al. Iron regulates T-lymphocyte sensitivity to the IFN-gamma\/STAT1 signaling pathway in vitro and in vivo. Blood. 2005;105:3214\u201321.","journal-title":"Blood"},{"key":"1397_CR100","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1111\/j.1349-7006.2009.01131.x","volume":"100","author":"JH Ohyashiki","year":"2009","unstructured":"Ohyashiki JH, Kobayashi C, Hamamura R, Okabe S, Tauchi T, Ohyashiki K. The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1. Cancer Sci. 2009;100:970\u20137.","journal-title":"Cancer Sci"},{"key":"1397_CR101","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.exphem.2018.10.010","volume":"70","author":"S Shapira","year":"2019","unstructured":"Shapira S, Raanani P, Samara A, Nagler A, Lubin I, Arber N, et al. Deferasirox selectively induces cell death in the clinically relevant population of leukemic CD34(+)CD38(\u2212) cells through iron chelation, induction of ROS, and inhibition of HIF1alpha expression. Exp Hematol. 2019;70:55\u201369 e54.","journal-title":"Exp Hematol"},{"key":"1397_CR102","first-page":"14","volume":"16","author":"L Yalcintepe","year":"2016","unstructured":"Yalcintepe L, Halis E. Modulation of iron metabolism by iron chelation regulates intracellular calcium and increases sensitivity to doxorubicin. Bosn J Basic Med Sci. 2016;16:14\u201320.","journal-title":"Bosn J Basic Med Sci"},{"key":"1397_CR103","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1046\/j.1365-2141.1998.00834.x","volume":"102","author":"A Leardi","year":"1998","unstructured":"Leardi A, Caraglia M, Selleri C, Pepe S, Pizzi C, Notaro R, et al. Desferioxamine increases iron depletion and apoptosis induced by ara-C of human myeloid leukaemic cells. Br J Haematol. 1998;102:746\u201352.","journal-title":"Br J Haematol"},{"key":"1397_CR104","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.leukres.2014.05.005","volume":"38","author":"R Yu","year":"2014","unstructured":"Yu R, Wang D, Ren X, Zeng L, Liu Y. The growth-inhibitory and apoptosis-inducing effect of deferoxamine combined with arsenic trioxide on HL-60 xenografts in nude mice. Leuk Res. 2014;38:1085\u201390.","journal-title":"Leuk Res"},{"key":"1397_CR105","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/S0145-2126(03)00118-8","volume":"27","author":"FJ Giles","year":"2003","unstructured":"Giles FJ, Fracasso PM, Kantarjian HM, Cortes JE, Brown RA, Verstovsek S, et al. Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leuk Res. 2003;27:1077\u201383.","journal-title":"Leuk Res"},{"key":"1397_CR106","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/ajh.21350","volume":"84","author":"E Noulsri","year":"2009","unstructured":"Noulsri E, Richardson DR, Lerdwana S, Fucharoen S, Yamagishi T, Kalinowski DS, et al. Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells. Am J Hematol. 2009;84:170\u20136.","journal-title":"Am J Hematol"},{"key":"1397_CR107","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/ajh.23640","volume":"89","author":"MD Minden","year":"2014","unstructured":"Minden MD, Hogge DE, Weir SJ, Kasper J, Webster DA, Patton L, et al. Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies. Am J Hematol. 2014;89:363\u20138.","journal-title":"Am J Hematol"},{"key":"1397_CR108","first-page":"1741","volume":"31","author":"T Fukushima","year":"2011","unstructured":"Fukushima T, Kawabata H, Nakamura T, Iwao H, Nakajima A, Miki M, et al. Iron chelation therapy with deferasirox induced complete remission in a patient with chemotherapy-resistant acute monocytic leukemia. Anticancer Res. 2011;31:1741\u20134.","journal-title":"Anticancer Res"},{"key":"1397_CR109","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1097\/TP.0b013e3181c42944","volume":"89","author":"P Kaloyannidis","year":"2010","unstructured":"Kaloyannidis P, Yannaki E, Sakellari I, Bitzioni E, Athanasiadou A, Mallouri D, et al. The impact of desferrioxamine postallogeneic hematopoietic cell transplantation in relapse incidence and disease-free survival: a retrospective analysis. Transplantation. 2010;89:472\u20139.","journal-title":"Transplantation"},{"key":"1397_CR110","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/bmt.2012.94","volume":"48","author":"P Armand","year":"2013","unstructured":"Armand P, Sainvil MM, Kim HT, Rhodes J, Cutler C, Ho VT, et al. Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative Allo-SCT. Bone Marrow Transplant. 2013;48:146\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"1397_CR111","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/cam4.1928","volume":"8","author":"BS Cho","year":"2019","unstructured":"Cho BS, Jeon YW, Hahn AR, Lee TH, Park SS, Yoon JH, et al. Improved survival outcomes and restoration of graft-vs-leukemia effect by deferasirox after allogeneic stem cell transplantation in acute myeloid leukemia. Cancer Med. 2019;8:501\u201314.","journal-title":"Cancer Med"},{"key":"1397_CR112","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.leukres.2012.03.018","volume":"36","author":"V Pullarkat","year":"2012","unstructured":"Pullarkat V, Sehgal A, Li L, Meng Z, Lin A, Forman S, et al. Deferasirox exposure induces reactive oxygen species and reduces growth and viability of myelodysplastic hematopoietic progenitors. Leuk Res. 2012;36:966\u201373.","journal-title":"Leuk Res"},{"key":"1397_CR113","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/bmt.2013.213","volume":"49","author":"G Visani","year":"2014","unstructured":"Visani G, Guiducci B, Giardini C, Loscocco F, Ricciardi T, Isidori A. Deferasirox improves hematopoiesis after allogeneic hematopoietic SCT. Bone Marrow Transplant. 2014;49:585\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"1397_CR114","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.leukres.2005.12.013","volume":"30","author":"KW Yee","year":"2006","unstructured":"Yee KW, Cortes J, Ferrajoli A, Garcia-Manero G, Verstovsek S, Wierda W, et al. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. Leuk Res. 2006;30:813\u201322.","journal-title":"Leuk Res"},{"key":"1397_CR115","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10637-008-9115-6","volume":"26","author":"OM Odenike","year":"2008","unstructured":"Odenike OM, Larson RA, Gajria D, Dolan ME, Delaney SM, Karrison TG, et al. Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Investig New Drugs. 2008;26:233\u20139.","journal-title":"Investig New Drugs"},{"key":"1397_CR116","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.leukres.2007.05.003","volume":"32","author":"JE Karp","year":"2008","unstructured":"Karp JE, Giles FJ, Gojo I, Morris L, Greer J, Johnson B, et al. A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders. Leuk Res. 2008;32:71\u20137.","journal-title":"Leuk Res"},{"key":"1397_CR117","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3324\/haematol.2013.097246","volume":"99","author":"JF Zeidner","year":"2014","unstructured":"Zeidner JF, Karp JE, Blackford AL, Smith BD, Gojo I, Gore SD, et al. A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms. Haematologica. 2014;99:672\u20138.","journal-title":"Haematologica"},{"key":"1397_CR118","doi-asserted-by":"publisher","first-page":"e417","DOI":"10.1016\/S2352-3026(15)00149-0","volume":"2","author":"U Platzbecker","year":"2015","unstructured":"Platzbecker U, Wong RS, Verma A, Abboud C, Araujo S, Chiou TJ, et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1\/2 trial. Lancet Haematol. 2015;2:e417\u201326.","journal-title":"Lancet Haematol"},{"key":"1397_CR119","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1016\/S2352-3026(18)30231-X","volume":"6","author":"N Frey","year":"2019","unstructured":"Frey N, Jang JH, Szer J, Illes A, Kim HJ, Ram R, et al. Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study. Lancet Haematol. 2019;6:e122\u201331.","journal-title":"Lancet Haematol"},{"key":"1397_CR120","first-page":"1759","volume":"46","author":"R Taetle","year":"1986","unstructured":"Taetle R, Castagnola J, Mendelsohn J. Mechanisms of growth inhibition by anti-transferrin receptor monoclonal antibodies. Cancer Res. 1986;46:1759\u201363.","journal-title":"Cancer Res"},{"key":"1397_CR121","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/sj.leu.2404958","volume":"22","author":"C Callens","year":"2008","unstructured":"Callens C, Moura IC, Lepelletier Y, Coulon S, Renand A, Dussiot M, et al. Recent advances in adult T-cell leukemia therapy: focus on a new anti-transferrin receptor monoclonal antibody. Leukemia. 2008;22:42\u20138.","journal-title":"Leukemia"},{"key":"1397_CR122","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1182\/blood-2003-07-2440","volume":"103","author":"IC Moura","year":"2004","unstructured":"Moura IC, Lepelletier Y, Arnulf B, England P, Baude C, Beaumont C, et al. A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients. Blood. 2004;103:1838\u201345.","journal-title":"Blood"},{"key":"1397_CR123","first-page":"6295","volume":"50","author":"S White","year":"1990","unstructured":"White S, Taetle R, Seligman PA, Rutherford M, Trowbridge IS. Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: evidence for synergistic antiproliferative effects. Cancer Res. 1990;50:6295\u2013301.","journal-title":"Cancer Res"},{"key":"1397_CR124","first-page":"4144","volume":"52","author":"JD Kemp","year":"1992","unstructured":"Kemp JD, Thorson JA, Stewart BC, Naumann PW. Inhibition of hematopoietic tumor growth by combined treatment with deferoxamine and an IgG monoclonal antibody against the transferrin receptor: evidence for a threshold model of iron deprivation toxicity. Cancer Res. 1992;52:4144\u20138.","journal-title":"Cancer Res"},{"key":"1397_CR125","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.bbrc.2017.02.039","volume":"485","author":"S Shimosaki","year":"2017","unstructured":"Shimosaki S, Nakahata S, Ichikawa T, Kitanaka A, Kameda T, Hidaka T, et al. Development of a complete human IgG monoclonal antibody to transferrin receptor 1 targeted for adult T-cell leukemia\/lymphoma. Biochem Biophys Res Commun. 2017;485:144\u201351.","journal-title":"Biochem Biophys Res Commun"},{"key":"1397_CR126","first-page":"747","volume":"47","author":"CA Sauvage","year":"1987","unstructured":"Sauvage CA, Mendelsohn JC, Lesley JF, Trowbridge IS. Effects of monoclonal antibodies that block transferrin receptor function on the in vivo growth of a syngeneic murine leukemia. Cancer Res. 1987;47:747\u201353.","journal-title":"Cancer Res"},{"key":"1397_CR127","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/1472-6750-12-92","volume":"12","author":"D Zhang","year":"2012","unstructured":"Zhang D, Lee HF, Pettit SC, Zaro JL, Huang N, Shen WC. Characterization of transferrin receptor-mediated endocytosis and cellular iron delivery of recombinant human serum transferrin from rice (Oryza sativa L.). BMC Biotechnol. 2012;12:92.","journal-title":"BMC Biotechnol"},{"key":"1397_CR128","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.canlet.2008.08.031","volume":"274","author":"S Oh","year":"2009","unstructured":"Oh S, Kim BJ, Singh NP, Lai H, Sasaki T. Synthesis and anti-cancer activity of covalent conjugates of artemisinin and a transferrin-receptor targeting peptide. Cancer Lett. 2009;274:33\u20139.","journal-title":"Cancer Lett"},{"key":"1397_CR129","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1182\/blood.V74.6.2043.2043","volume":"74","author":"KM Hege","year":"1989","unstructured":"Hege KM, Daleke DL, Waldmann TA, Matthay KK. Comparison of anti-tac and anti-transferrin receptor-conjugated liposomes for specific drug delivery to adult T-cell leukemia. Blood. 1989;74:2043\u201352.","journal-title":"Blood"},{"key":"1397_CR130","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1021\/mp300172e","volume":"9","author":"AP Retnakumari","year":"2012","unstructured":"Retnakumari AP, Hanumanthu PL, Malarvizhi GL, Prabhu R, Sidharthan N, Thampi MV, et al. Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated\/amplified refractory chronic myeloid leukemia. Mol Pharm. 2012;9:3062\u201378.","journal-title":"Mol Pharm"},{"key":"1397_CR131","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/bit.22858","volume":"107","author":"LS Mendonca","year":"2010","unstructured":"Mendonca LS, Moreira JN, de Lima MC, Simoes S. Co-encapsulation of anti-BCR-ABL siRNA and imatinib mesylate in transferrin receptor-targeted sterically stabilized liposomes for chronic myeloid leukemia treatment. Biotechnol Bioeng. 2010;107:884\u201393.","journal-title":"Biotechnol Bioeng"},{"key":"1397_CR132","first-page":"1287128","volume":"2016","author":"Y Yuan","year":"2016","unstructured":"Yuan Y, Zhang L, Cao H, Yang Y, Zheng Y, Yang XJ. A Polyethylenimine-containing and transferrin-conjugated lipid nanoparticle system for antisense oligonucleotide delivery to AML. Biomed Res Int. 2016;2016:1287128.","journal-title":"Biomed Res Int"},{"key":"1397_CR133","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1021\/mp800149s","volume":"6","author":"X Yang","year":"2009","unstructured":"Yang X, Koh CG, Liu S, Pan X, Santhanam R, Yu B, et al. Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2. Mol Pharm. 2009;6:221\u201330.","journal-title":"Mol Pharm"},{"issue":"6","key":"1397_CR134","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.3390\/molecules23061289","volume":"23","author":"Isra\u2019 Zeiadeh","year":"2018","unstructured":"Zeiadeh I, Najjar A, Karaman R. Strategies for enhancing the permeation of CNS-active drugs through the blood-brain barrier: a review. Molecules. 2018;23:1289.","journal-title":"Molecules"},{"key":"1397_CR135","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/1479-5876-9-191","volume":"9","author":"S Hayashi","year":"2011","unstructured":"Hayashi S, Kumai T, Matsuda Y, Aoki N, Sato K, Kimura S, et al. Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer. J Transl Med. 2011;9:191.","journal-title":"J Transl Med"},{"key":"1397_CR136","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161509","volume":"11","author":"J Wu","year":"2016","unstructured":"Wu J, Liu H, Zhang G, Gu L, Zhang Y, Gao J, et al. Antileukemia effect of Ciclopirox Olamine is mediated by downregulation of intracellular ferritin and inhibition beta-catenin-c-Myc signaling pathway in glucocorticoid resistant T-ALL cell lines. PLoS One. 2016;11:e0161509.","journal-title":"PLoS One"},{"key":"1397_CR137","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1021\/cr400011b","volume":"115","author":"G Jutz","year":"2015","unstructured":"Jutz G, van Rijn P, Santos Miranda B, Boker A. Ferritin: a versatile building block for bionanotechnology. Chem Rev. 2015;115:1653\u2013701.","journal-title":"Chem Rev"},{"key":"1397_CR138","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.exphem.2006.06.019","volume":"34","author":"MJ Huang","year":"2006","unstructured":"Huang MJ, Cheng YC, Liu CR, Lin S, Liu HE. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Exp Hematol. 2006;34:1480\u20139.","journal-title":"Exp Hematol"},{"key":"1397_CR139","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.leukres.2014.11.004","volume":"39","author":"B Xia","year":"2015","unstructured":"Xia B, Tian C, Guo S, Zhang L, Zhao D, Qu F, et al. C-Myc plays part in drug resistance mediated by bone marrow stromal cells in acute myeloid leukemia. Leuk Res. 2015;39:92\u20139.","journal-title":"Leuk Res"},{"key":"1397_CR140","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060\u201372.","journal-title":"Cell"},{"key":"1397_CR141","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13046-018-0733-3","volume":"37","author":"B Zhao","year":"2018","unstructured":"Zhao B, Li X, Wang Y, Shang P. Iron-dependent cell death as executioner of cancer stem cells. J Exp Clin Cancer Res. 2018;37:79.","journal-title":"J Exp Clin Cancer Res"},{"key":"1397_CR142","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.molcel.2015.06.011","volume":"59","author":"M Gao","year":"2015","unstructured":"Gao M, Monian P, Quadri N, Ramasamy R, Jiang X. Glutaminolysis and transferrin regulate Ferroptosis. Mol Cell. 2015;59:298\u2013308.","journal-title":"Mol Cell"},{"key":"1397_CR143","doi-asserted-by":"publisher","first-page":"5617","DOI":"10.1038\/onc.2015.32","volume":"34","author":"X Sun","year":"2015","unstructured":"Sun X, Ou Z, Xie M, Kang R, Fan Y, Niu X, et al. HSPB1 as a novel regulator of ferroptotic cancer cell death. Oncogene. 2015;34:5617\u201325.","journal-title":"Oncogene"},{"key":"1397_CR144","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1080\/15548627.2016.1187366","volume":"12","author":"W Hou","year":"2016","unstructured":"Hou W, Xie Y, Song X, Sun X, Lotze MT, Zeh HJ 3rd, et al. Autophagy promotes ferroptosis by degradation of ferritin. Autophagy. 2016;12:1425\u20138.","journal-title":"Autophagy"},{"key":"1397_CR145","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","volume":"156","author":"WS Yang","year":"2014","unstructured":"Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156:317\u201331.","journal-title":"Cell"},{"key":"1397_CR146","first-page":"3289","volume":"2013","author":"R Brigelius-Flohe","year":"1830","unstructured":"Brigelius-Flohe R, Maiorino M. Glutathione peroxidases. Biochim Biophys Acta. 1830;2013:3289\u2013303.","journal-title":"Biochim Biophys Acta"},{"key":"1397_CR147","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.02523","volume":"3","author":"SJ Dixon","year":"2014","unstructured":"Dixon SJ, Patel DN, Welsch M, Skouta R, Lee ED, Hayano M, et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife. 2014;3:e02523.","journal-title":"Elife"},{"key":"1397_CR148","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature14344","volume":"520","author":"L Jiang","year":"2015","unstructured":"Jiang L, Kon N, Li T, Wang SJ, Su T, Hibshoosh H, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015;520:57\u201362.","journal-title":"Nature"},{"key":"1397_CR149","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1002\/ijc.28159","volume":"133","author":"C Louandre","year":"2013","unstructured":"Louandre C, Ezzoukhry Z, Godin C, Barbare JC, Maziere JC, Chauffert B, et al. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. Int J Cancer. 2013;133:1732\u201342.","journal-title":"Int J Cancer"},{"key":"1397_CR150","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13045-019-0720-y","volume":"12","author":"Y Mou","year":"2019","unstructured":"Mou Y, Wang J, Wu J, He D, Zhang C, Duan C, et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J Hematol Oncol. 2019;12:34.","journal-title":"J Hematol Oncol"},{"key":"1397_CR151","doi-asserted-by":"publisher","DOI":"10.1080\/23723556.2015.1054549","volume":"2","author":"Y Yu","year":"2015","unstructured":"Yu Y, Xie Y, Cao L, Yang L, Yang M, Lotze MT, et al. The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents. Mol Cell Oncol. 2015;2:e1054549.","journal-title":"Mol Cell Oncol"},{"key":"1397_CR152","doi-asserted-by":"publisher","first-page":"63779","DOI":"10.18632\/oncotarget.11687","volume":"7","author":"J Dachert","year":"2016","unstructured":"Dachert J, Schoeneberger H, Rohde K, Fulda S. RSL3 and Erastin differentially regulate redox signaling to promote Smac mimetic-induced cell death. Oncotarget. 2016;7:63779\u201392.","journal-title":"Oncotarget"},{"key":"1397_CR153","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.bcp.2017.06.112","volume":"140","author":"L Probst","year":"2017","unstructured":"Probst L, Dachert J, Schenk B, Fulda S. Lipoxygenase inhibitors protect acute lymphoblastic leukemia cells from ferroptotic cell death. Biochem Pharmacol. 2017;140:41\u201352.","journal-title":"Biochem Pharmacol"},{"key":"1397_CR154","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1002\/cncr.30680","volume":"123","author":"G Battipaglia","year":"2017","unstructured":"Battipaglia G, Ruggeri A, Massoud R, El Cheikh J, Jestin M, Antar A, et al. Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia. Cancer. 2017;123:2867\u201374.","journal-title":"Cancer"},{"key":"1397_CR155","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.ejca.2017.09.016","volume":"86","author":"SK Metzelder","year":"2017","unstructured":"Metzelder SK, Schroeder T, Lubbert M, Ditschkowski M, Gotze K, Scholl S, et al. Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation. Eur J Cancer. 2017;86:233\u20139.","journal-title":"Eur J Cancer"},{"key":"1397_CR156","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1038\/nature01813","volume":"424","author":"U Eckstein-Ludwig","year":"2003","unstructured":"Eckstein-Ludwig U, Webb RJ, Van Goethem ID, East JM, Lee AG, Kimura M, et al. Artemisinins target the SERCA of plasmodium falciparum. Nature. 2003;424:957\u201361.","journal-title":"Nature"},{"key":"1397_CR157","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.freeradbiomed.2018.12.011","volume":"131","author":"J Du","year":"2019","unstructured":"Du J, Wang T, Li Y, Zhou Y, Wang X, Yu X, et al. DHA inhibits proliferation and induces ferroptosis of leukemia cells through autophagy dependent degradation of ferritin. Free Radic Biol Med. 2019;131:356\u201369.","journal-title":"Free Radic Biol Med"},{"key":"1397_CR158","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.phymed.2015.08.002","volume":"22","author":"E Ooko","year":"2015","unstructured":"Ooko E, Saeed ME, Kadioglu O, Sarvi S, Colak M, Elmasaoudi K, et al. Artemisinin derivatives induce iron-dependent cell death (ferroptosis) in tumor cells. Phytomedicine. 2015;22:1045\u201354.","journal-title":"Phytomedicine"},{"key":"1397_CR159","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.phymed.2017.12.016","volume":"48","author":"AT Mbaveng","year":"2018","unstructured":"Mbaveng AT, Fotso GW, Ngnintedo D, Kuete V, Ngadjui BT, Keumedjio F, et al. Cytotoxicity of epunctanone and four other phytochemicals isolated from the medicinal plants Garcinia epunctata and Ptycholobium contortum towards multi-factorial drug resistant cancer cells. Phytomedicine. 2018;48:112\u20139.","journal-title":"Phytomedicine"},{"key":"1397_CR160","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.phymed.2018.03.035","volume":"43","author":"AT Mbaveng","year":"2018","unstructured":"Mbaveng AT, Ndontsa BL, Kuete V, Nguekeu YMM, Celik I, Mbouangouere R, et al. A naturally occuring triterpene saponin ardisiacrispin B displayed cytotoxic effects in multi-factorial drug resistant cancer cells via ferroptotic and apoptotic cell death. Phytomedicine. 2018;43:78\u201385.","journal-title":"Phytomedicine"},{"key":"1397_CR161","first-page":"1933","volume":"8","author":"S Wang","year":"2018","unstructured":"Wang S, Luo J, Zhang Z, Dong D, Shen Y, Fang Y, et al. Iron and magnetic: new research direction of the ferroptosis-based cancer therapy. Am J Cancer Res. 2018;8:1933\u201346.","journal-title":"Am J Cancer Res"},{"key":"1397_CR162","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.2147\/IJN.S59661","volume":"9","author":"F Namvar","year":"2014","unstructured":"Namvar F, Rahman HS, Mohamad R, Baharara J, Mahdavi M, Amini E, et al. Cytotoxic effect of magnetic iron oxide nanoparticles synthesized via seaweed aqueous extract. Int J Nanomedicine. 2014;9:2479\u201388.","journal-title":"Int J Nanomedicine"},{"key":"1397_CR163","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201704007","volume":"30","author":"Z Shen","year":"2018","unstructured":"Shen Z, Song J, Yung BC, Zhou Z, Wu A, Chen X. Emerging strategies of cancer therapy based on Ferroptosis. Adv Mater. 2018;30:e1704007.","journal-title":"Adv Mater"},{"key":"1397_CR164","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1053\/j.ajkd.2016.04.018","volume":"68","author":"D Shepshelovich","year":"2016","unstructured":"Shepshelovich D, Rozen-Zvi B, Avni T, Gafter U, Gafter-Gvili A. Intravenous versus Oral iron supplementation for the treatment of anemia in CKD: an updated systematic review and meta-analysis. Am J Kidney Dis. 2016;68:677\u201390.","journal-title":"Am J Kidney Dis"},{"key":"1397_CR165","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.colsurfb.2016.01.054","volume":"141","author":"N Shahabadi","year":"2016","unstructured":"Shahabadi N, Falsafi M, Mansouri K. Improving antiproliferative effect of the anticancer drug cytarabine on human promyelocytic leukemia cells by coating on Fe3O4@SiO2 nanoparticles. Colloids Surf B Biointerfaces. 2016;141:213\u201322.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"1397_CR166","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/bjh.13066","volume":"167","author":"N Satake","year":"2014","unstructured":"Satake N, Duong C, Chen C, Barisone GA, Diaz E, Tuscano J, et al. Targeted therapy with MXD3 siRNA, anti-CD22 antibody and nanoparticles for precursor B-cell acute lymphoblastic leukaemia. Br J Haematol. 2014;167:487\u201399.","journal-title":"Br J Haematol"},{"key":"1397_CR167","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.2147\/IJN.S62260","volume":"9","author":"Z Sun","year":"2014","unstructured":"Sun Z, Worden M, Wroczynskyj Y, Yathindranath V, van Lierop J, Hegmann T, et al. Magnetic field enhanced convective diffusion of iron oxide nanoparticles in an osmotically disrupted cell culture model of the blood-brain barrier. Int J Nanomedicine. 2014;9:3013\u201326.","journal-title":"Int J Nanomedicine"},{"key":"1397_CR168","doi-asserted-by":"publisher","first-page":"3164","DOI":"10.1016\/j.biomaterials.2013.12.098","volume":"35","author":"V Zablotskii","year":"2014","unstructured":"Zablotskii V, Syrovets T, Schmidt ZW, Dejneka A, Simmet T. Modulation of monocytic leukemia cell function and survival by high gradient magnetic fields and mathematical modeling studies. Biomaterials. 2014;35:3164\u201371.","journal-title":"Biomaterials"},{"key":"1397_CR169","first-page":"63","volume":"13","author":"RM Patil","year":"2018","unstructured":"Patil RM, Thorat ND, Shete PB, Bedge PA, Gavde S, Joshi MG, et al. Comprehensive cytotoxicity studies of superparamagnetic iron oxide nanoparticles. Biochem Biophys Rep. 2018;13:63\u201372.","journal-title":"Biochem Biophys Rep"},{"key":"1397_CR170","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3389\/fimmu.2019.00224","volume":"10","author":"R Sottile","year":"2019","unstructured":"Sottile R, Federico G, Garofalo C, Tallerico R, Faniello MC, Quaresima B, et al. Iron and ferritin modulate MHC class I expression and NK cell recognition. Front Immunol. 2019;10:224.","journal-title":"Front Immunol"},{"key":"1397_CR171","doi-asserted-by":"publisher","first-page":"11105","DOI":"10.1073\/pnas.0804226105","volume":"105","author":"Q Chen","year":"2008","unstructured":"Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, Krishna MC, et al. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci U S A. 2008;105:11105\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1397_CR172","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/nature23876","volume":"549","author":"M Agathocleous","year":"2017","unstructured":"Agathocleous M, Meacham CE, Burgess RJ, Piskounova E, Zhao Z, Crane GM, et al. Ascorbate regulates haematopoietic stem cell function and leukaemogenesis. Nature. 2017;549:476\u201381.","journal-title":"Nature"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-019-1397-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13046-019-1397-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-019-1397-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T23:11:19Z","timestamp":1599865879000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-019-1397-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,13]]},"references-count":172,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1397"],"URL":"https:\/\/doi.org\/10.1186\/s13046-019-1397-3","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,13]]},"assertion":[{"value":"1 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This is not applicable for this review.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This is not applicable for this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"406"}}